((8R,9S,10S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate | 59877-74-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: ((8R,9S,10S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate
• 英文别名: 19-Hydroxy-androst-4-en-3,17-dion-19-p-tosylat；19-p-Toluolsulfonyloxy-androst-4-en-3,17-dion；[(8R,9S,10S,13S,14S)-13-methyl-3,17-dioxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-10-yl]methyl 4-methylbenzenesulfonate
• CAS: 59877-74-6
• 化学式: C₂₆H₃₂O₅S
• 分子量: 456.603
• InChiKey: JSEONXJKSHDLSE-QKYIWSEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  85.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ((8R,9S,10S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate 在 platinum(IV) oxide 、 bis(triphenylphosphine) palladium (Il) acetate platinum(IV) oxide 、 potassium permanganate 、 sodium periodate 、 2,6-二叔丁基-4-甲基吡啶 、 jones' reagent 、 氢气 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 乙酸乙酯 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 生成 C₂₇H₄₄N₂O₂
  参考文献：
  名称：

  新型桥环类固醇的合成

  摘要：

  合成了新型桥连的A环类固醇作为类固醇5α-还原酶的潜在抑制剂。通过X射线分析证实了关键的合成中间体五环烯二酮的结构。

  DOI：

  10.1016/s0040-4039(00)61823-3
• 作为产物：
  描述：

  雄烯二酮 在 吡啶 、 过氧化氢异丙苯 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 ((8R,9S,10S,13S,14S)-13-methyl-3,17-dioxo-1,2,3,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-10H-cyclopenta[a]phenanthren-10-yl)methyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  EP3750909

  摘要：

  公开号：

文献信息

• Steroids cclix11Part CCLVIII. J. Romo, L. Rodriguez-Hahn, P. Joseph-Nathan, M. Martínez and P. Crabbe. Bull. Soc.Chim. France (submitted for publication).. The synthesis of 5β,19 and 6β,19-cyclo steroids
  作者：O. Halpern、P. Crabbé、A.D. Cross、I. Delfin、L. Cervantes、A. Bowers

  DOI：10.1016/0039-128x(64)90022-4

  日期：1964.7

  Abstract The solvolysis of 3β,19-dihydroxyandrost-5-ene-17-one-3-acetate 19-tosylate (Ib) led to the Δ6-5, 19-cyclo steroid IIa or a variety of 6α-substituted 5,19-cyclopropanes V depending upon the reaction conditions. The possibility that these reactions proceed through an intermediate homoallylic bridged cation is discussed. The formation of 6β,19-cyclobutanes from 19-hydroxyandrost-4-ene 3,17-dione

  摘要 3β,19-dihydroxyandrost-5-ene-17-one-3-acetate 19-tosylate (Ib) 的溶剂分解产生了 Δ6-5, 19-环类固醇 IIa 或各种 6α-取代的 5,19-环丙烷 V 取决于反应条件。讨论了这些反应通过中间同烯丙基桥接阳离子进行的可能性。描述了从 19-羟基雄甾醇-4-烯 3,17-二酮甲苯磺酸酯 (VIb) 形成 6β,19-环丁烷
• STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：EP3750909A1

  公开（公告）日：2020-12-16

  The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.

  本发明涉及类固醇衍生物调节剂、其制备方法及其用途。具体而言，本发明涉及一种如式（I）所示的化合物、其制备方法、含有该化合物的药物组合物及其作为 GABA A 受体调节剂用于治疗抑郁症、抽搐、帕金森病和神经系统疾病的用途，其中式（I）的取代基如描述中所定义。
• 6β,19-Bridged androstenedione analogs as aromatase inhibitors
  作者：Sachiko Komatsu、Ayaka Yaguchi、Kouwa Yamashita、Masao Nagaoka、Mitsuteru Numazawa

  DOI：10.1016/j.steroids.2009.06.001

  日期：2009.11

  Inhibition of aromatase is an efficient approach for the prevention and treatment of breast cancer. New 6 beta,19-bridged steroid analogs of androstenedione, 6 beta,19-epithio- and 6 beta,19-methano compounds 11 and 17, were synthesized starting from 19-hydroxyand rostenedione (6) and 19-formylandrost-5-ene-3 beta,17 beta-yl diacetate (12), respectively, as aromatase inhibitors. All of the compounds including known steroids 6 beta,19-epoxyandrostenedione (4) and 6 beta,19-cycloandrostenedione (5) tested were weak to poor competitive inhibitors of aromatase and, among them, 6 beta,19-epoxy steroid 4 provided only moderate inhibition (K-i: 2.2 mu M). These results show that the 6 beta,19-bridged groups of the inhibitors interfere with binding in active site of aromatase. (C) 2009 Elsevier Inc. All rights reserved.
• Steroids. CCLXXVIII.¹ Reductions of 19-Substituted Androst-4-en-3-ones and Related Compounds
  作者：L. H. Knox、E. Blossey、H. Carpio、L. Cervantes、P. Crabbé、E. Velarde、J. A. Edwards

  DOI：10.1021/jo01018a019

  日期：1965.7
• EP3750909
  申请人：——

  公开号：——

  公开（公告）日：——